Catherine M. Szyman - 08 Sep 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, Critical Care
Signature: Linda J. Park, Attorney-in-Fact
Issuer symbol: EW
Transactions as of: 08 Sep 2021
Net transactions value: -$969,398
Form type: 4
Filing time: 08 Sep 2021, 21:04:40 UTC
Previous filing: 05 Aug 2021
Next filing: 18 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$211,964	+9,741	+36%	$21.76	37,156	08 Sep 2021	Direct	F1
transaction	EW	Common Stock	Sale	$1,181,362	-9,741	-26%	$121.28	27,415	08 Sep 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-9,741	-7.3%	$0.000000	123,141	08 Sep 2021	Common Stock	9,741	$21.76	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021.
F2	This transaction was executed in multiple trades at prices ranging from $120.9950 to $121.7000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.